• 1
    Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010; 50: 347353.
  • 2
    Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008; 197: 1017.
  • 3
    Desmet S, Van Wijngaerden E, Maertens J et al. Serum (1-3)-beta-d-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy. J Clin Microbiol 2009; 47: 38713874.
  • 4
    Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A. Contribution of the (1[RIGHTWARDS ARROW]3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2008; 46: 10091013.
  • 5
    Shimizu A, Oka H, Matsuda T, Ozaki S. (1[RIGHTWARDS ARROW]3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol 2005; 23: 678680.
  • 6
    Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Mod Rheumatol 2006; 16: 282288.
  • 7
    Nakamura H, Tateyama M, Tasato D et al. Clinical utility of serum beta-D-glucan and KL-6 levels in Pneumocystis jirovecii pneumonia. Intern Med 2009; 48: 195202.
  • 8
    Watanabe T, Yasuoka A, Tanuma J et al. Serum (1[RIGHTWARDS ARROW]3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS. Clin Infect Dis 2009; 49: 11281131.
  • 9
    Yasuoka A, Tachikawa N, Shimada K, Kimura S, Oka S. (1[RIGHTWARDS ARROW]3) beta-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 1996; 3: 197199.
  • 10
    Obayashi T, Yoshida M, Mori T et al. Plasma (1[RIGHTWARDS ARROW]3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345: 1720.
  • 11
    Probst M, Ries H, Schmidt-Wieland T, Serr A. Detection of Pneumocystis carinii DNA in patients with chronic lung diseases. Eur J Clin Microbiol Infect Dis 2000; 19: 644645.
  • 12
    Larsen HH, Masur H, Kovacs JA et al. Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia. J Clin Microbiol 2002; 40: 490494.
  • 13
    Ikemura K, Ikegami K, Shimazu T, Yoshioka T, Sugimoto T. False-positive result in Limulus test caused by Limulus amebocyte lysate-reactive material in immunoglobulin products. J Clin Microbiol 1989; 27: 19651968.
  • 14
    Kanda H, Kubo K, Hamasaki K et al. Influence of various hemodialysis membranes on the plasma (1[RIGHTWARDS ARROW]3)-β-D-glucan level. Kidney Int 2001; 60: 319323.
  • 15
    Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A. Elevation of blood (1[RIGHTWARDS ARROW]3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 1519.
  • 16
    Ogawa M, Hori H, Niiguchi S, Azuma E, Komada Y. False positive plasma (1[RIGHTWARDS ARROW]3)-β-D-glucan following immunoglobulin product replacement in adult bone marrow recipient. Int J Hematol 2004; 80: 9798.
  • 17
    Usami M, Ohata A, Horiuchi T, Nagasawa K, Wakabayashi T, Tanaka S. Positive (1[RIGHTWARDS ARROW]3)-beta-D-glucan in blood components and release of (1[RIGHTWARDS ARROW]3)-beta-D-glucan from depth-type membrane filters for blood processing. Transfusion 2002; 42: 11891195.
  • 18
    Ohata A, Usami M, Horiuchi T, Nagasawa K, Kinoshita K. Release of (1[RIGHTWARDS ARROW]3)-beta-D-glucan from depth-type membrane filters and their in vitro effects on proinflammatory cytokine production. Artif Organs 2003; 27: 728735.
  • 19
    Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007; 13: 17.
  • 20
    Cuétara MS, Alhambra A, Chaves F, Moragues MD, Pontón J, del Palacio A. Use of a serum (1[RIGHTWARDS ARROW]3)-beta-D-glucan assay for diagnosis and follow-up of Pneumocystis jiroveci pneumonia. Clin Infect Dis 2008; 47: 13641366.
  • 21
    Yoshida M, Roth RI, Grunfeld C, Feingold KR, Levin J. Soluble (1[RIGHTWARDS ARROW]3)-beta-D-glucan purified from Candida albicans: biologic effects and distribution in blood and organs in rabbits. J Lab Clin Med 1996; 128: 103114.
  • 22
    Del Bono V, Mularoni A, Furfaro E et al. Clinical evaluation of a (1[RIGHTWARDS ARROW]3)-beta-D-glucan assay for presumptive diagnosis of Pneumocystis jiroveci pneumonia in immunocompromised patients. Clin Vaccine Immunol 2009; 16: 15241526.
  • 23
    Marty FM, Koo S, Bryar J, Baden LR. (1[RIGHTWARDS ARROW]3)-beta-D-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 2007; 147: 7072.
  • 24
    Tasaka S, Hasegawa N, Kobayashi S et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007; 131: 11731180.
  • 25
    Mennink-Kersten MA, Ruegebrink D, Verweij PE. Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity. Clin Infect Dis 2008; 46: 19301931.